↓ Skip to main content

Green tea and quercetin sensitize PC-3 xenograft prostate tumors to docetaxel chemotherapy

Overview of attention for article published in Journal of Experimental & Clinical Cancer Research, May 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

twitter
2 tweeters
facebook
1 Facebook page

Readers on

mendeley
61 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Green tea and quercetin sensitize PC-3 xenograft prostate tumors to docetaxel chemotherapy
Published in
Journal of Experimental & Clinical Cancer Research, May 2016
DOI 10.1186/s13046-016-0351-x
Pubmed ID
Authors

Piwen Wang, Susanne M. Henning, Clara E. Magyar, Yahya Elshimali, David Heber, Jaydutt V. Vadgama

Abstract

Chemotherapy with docetaxel (Doc) remains the standard treatment for metastatic and castration-resistance prostate cancer (CRPC). However, the clinical success of Doc is limited by its chemoresistance and side effects. This study investigated whether natural products green tea (GT) and quercetin (Q) enhance the therapeutic efficacy of Doc in CRPC in mouse models. Male severe combined immunodeficiency (SCID) mice (n = 10 per group) were inoculated with androgen-independent prostate cancer PC-3 cells subcutaneously. When tumors were established the intervention started. Mice were administered with GT + Q, Doc 5 mg/kg (LD), GT + Q + LD Doc, Doc 10 mg/kg (HD) or control. The concentration of GT polyphenols in brewed tea administered as drinking water was 0.07 % and Q was supplemented in diet at 0.4 %. Doc was intravenously injected weekly for 4 weeks, GT and Q given throughout the study. GT + Q or LD Doc slightly inhibited tumor growth compared to control. However, the combination of GT and Q with LD Doc significantly enhanced the potency of Doc 2-fold and reduced tumor growth by 62 % compared to LD Doc in 7-weeks intervention. A decrease of Ki67 and increase of cleaved caspase 7 were observed in tumors by the mixture, along with lowered blood concentrations of growth factors like VEGF and EGF. The mixture significantly elevated the levels of tumor suppressor mir15a and mir330 in tumor tissues. An increased risk of liver toxicity was only observed with HD Doc treatment. These results provide a promising regimen to enhance the therapeutic effect of Doc in a less toxic manner.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 61 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 8 13%
Researcher 8 13%
Student > Bachelor 8 13%
Other 5 8%
Professor 4 7%
Other 9 15%
Unknown 19 31%
Readers by discipline Count As %
Medicine and Dentistry 8 13%
Agricultural and Biological Sciences 7 11%
Biochemistry, Genetics and Molecular Biology 7 11%
Nursing and Health Professions 3 5%
Pharmacology, Toxicology and Pharmaceutical Science 3 5%
Other 12 20%
Unknown 21 34%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 May 2016.
All research outputs
#4,086,650
of 7,811,999 outputs
Outputs from Journal of Experimental & Clinical Cancer Research
#123
of 409 outputs
Outputs of similar age
#145,346
of 267,614 outputs
Outputs of similar age from Journal of Experimental & Clinical Cancer Research
#8
of 30 outputs
Altmetric has tracked 7,811,999 research outputs across all sources so far. This one is in the 27th percentile – i.e., 27% of other outputs scored the same or lower than it.
So far Altmetric has tracked 409 research outputs from this source. They receive a mean Attention Score of 1.5. This one has gotten more attention than average, scoring higher than 55% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 267,614 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.